The below finalists will be presenting their proposals at the FACTOR Conference on February 28th.
All FACTOR attendees will vote on February 29th and the winner will be announced at the closing of the conference.
Want to attend the FACTOR conference? CLICK HERE
The University of Texas,
MD Anderson Cancer Center
The University of Texas,
MD Anderson Cancer Center
Baylor College of Medicine
2020 MIB Agents OutSmarting Osteosarcoma Grant
MIB Agents is a nationwide 501(c)(3) non-profit organization dedicated to the mission to Make It Better for children with osteosarcoma, bone cancer. Each year a grant of $100,000 is awarded to a project that will focus on moving research forward for osteosarcoma patients. Proposals may be for a new project or an ongoing larger project for which results can be expected in twelve months. This year, the top three finalists for this grant will be required to present their proposal at FACTOR 2020.
At 12 months, results must be made available to share- regardless of the outcome of the research. The recipient must be available to present work underway and completed at the FACTOR Conference 2021, and may use grant funds for travel and accommodations to FACTOR conference. PI must also provide MIB Agents with a one page layman summary of outcomes to share with the community via website. Grant may not be used for the formation of a new organization, used for planning stages of research, or for any indirect costs.
Eligibility & Requirements:
MIB’s Unique Proposal Process:
#TogetherWeCan and #TogetherWeWill are not just fantastic tags but a philosophy that MIB Agents work to realize. Together, as a community, we will Make It Better. Our community includes researchers, patients, doctors, families and anyone working to Make It Better for osteosarcoma patients everywhere. Therefore, the FACTOR conference and OutSmarting Osteosarcoma Grant is attended and juried by members of the entire community- scientists, physicians, patients and families. Together We Will move the understanding and treatments of osteosarcoma forward.
Specific Application Details:
Application will be submitted online through the form located on this page.
Components of application:
By attending this meeting, you can vote for the three finalists that will then be voted on by all the attendees of the 2020 FACTOR conference. The winning proposal will receive $100,000 in osteosarcoma research funding from MIB Agents.
When: Tentatively November 8, 2019
Where: Video/Audio Conference Call
Want to Attend? To receive an invitation to this meeting you must have donated or raised $5,000 or more for Osteosarcoma Research to MIB Agents since January 1, 2019. Invitations to the meeting will be sent out in October.
To make your donation today, click HERE or mail your donation to: MIB Agents, PO Box 858, Barnard VT 05031
Click the button below to learn more about our past winners
and how this funding has helped move the needle in osteosarcoma.
Dr. Matteo Trucco received his training in Pediatric Hematology/Oncology from Johns Hopkins University and the National Cancer Institute and has focused his career primarily on Pediatric Sarcomas and the development of new therapies. As the Director of the Pediatric Phase 1 Program at the University of Miami-Sylvester Comprehensive Cancer Center he seeks to identify novel approaches to treating Pediatric Sarcomas, with a particular interest in targeting sarcomas’ metabolism, their hypoxic areas and sarcoma stem cells. He jumped at the opportunity to help bring together researchers, clinicians, patients and advocates as part of the FACTOR conference to stimulate innovation and collaboration to advance the research and treatment of Osteosarcoma.
He graduated summa cum laude from University of Minnesota, then began an MD, PhD program. This was completed at Mt. Sinai School of Medicine and City University of New York (Biochemical Genetics). Anderson then did a combined Internal Medicine/Pediatrics residency at Duke and Fellowship in Peds Heme/Onc/BMT at University of Minnesota – where he had a lab and obtained 3 patents. He then spent 10 years at Mayo (promoted to Professor) and was involved in some innovative osteosarcoma clinical trials including use of samarium. He was at MD Anderson Cancer Center 2005-2014 and tested mifamurtide, anti-IGFR, samarium, and 223Ra against osteosarcoma. Now at Cleveland Clinic, he remains active in patient advocacy and novel approaches to care of patients with sarcomas, especially osteosarcoma.
Ramy Ibrahim, MD, is a recognized leader of clinical development in immunotherapy. He helped develop some of the first breakthrough treatments in the field during his tenure at Bristol-Myers Squibb and MedImmune/AstraZeneca. Dr. Ibrahim currently serves as vice president of clinical development at the Parker Institute for Cancer Immunotherapy. Throughout his career, Dr. Ibrahim has been involved with global cancer immunotherapy societies such as the Society of Immunotherapy for Cancer (SITC), Ludwig Institute, the Cancer Research Institute and Cancer Immunotherapy Trials Network (CITN). He is a trained medical oncologist, who conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, MD.
Dr. Kaplan is a physician scientist who developed the concept of the pre-metastatic niche describing the changes in distant microenvironments in response to a growing tumor that create a niche environment conducive to disseminating tumor cell survival and growth resulting in clinically relevant metastasis. Dr. Kaplan has an active translational research program focusing on developing novel biomarkers and targets of the metastatic microenvironment by understanding the commonalities in mechanisms employed by a cancer cell to generate an entire heterogenous tumor at distant sites and stem cells and their niche to repopulate tissues.
Dr. Healey has decades of experience diagnosing and treating sarcomas and benign tumors of the bones and soft tissue. He is an expert in surgery to remove tumors while preserving limbs, and rebuild functional bones and joints with joint replacements and bone transplants. Dr. Healey has a special interest in treating children who have bone cancers (osteosarcoma and Ewing sarcoma). His research involves understanding the molecular biology of sarcoma, developing new ways to deliver chemotherapy to tumors, and improving the durability and function of joint replacements. Dr. Healey has invented and developed four different joint replacement systems and has patented several methods to deliver drugs to tumors and to study cancers in the laboratory. In addition to his role as Chief of the Orthopaedic Service at Memorial Soan-Kettering, he is a Professor of Orthopaedic Surgery at Weill Cornell Medical College. Nationally, Dr. Healey has served as Chair of the Children’s Oncology Group Orthopaedics Section, as President of the International Society of Limb Salvage, President of the Association of Bone and Joint Surgeons, and on the boards of several musculo- skeletal and orthopedic organizations.
Dr. Damon Reed is the Director of the Adolescent and Young Adult Program at Moffitt, the Medical Director of the Sarcoma Department at Moffitt Cancer Center and an Assistant Professor of Pediatrics at the University of South Florida. He is also an on staff as a specialty physician at All Children’s Hospital in St. Petersburg, FL. He is also the Leader of the Pediatric Cancer Foundation’s pediatric phase I consortium, the Sunshine Project. A graduate of Case Western Reserve University School of Medicine in Cleveland, OH, Dr. Reed served a combined pediatric residency program at Boston Children’s Hospital-Harvard Medical School and Boston Medical Center-Boston University School of Medicine. He completed his fellowship training in pediatric hematology/oncology at St. Jude Children’s Research Hospital. He received the CWRU Medical Alumni Association Board of Trustees Award for Outstanding Service and Contributions to the School of Medicine and was named to the Alpha Omega Alpha Honor Medical Society. Dr. Reed is a member of several professional associations, including the American Association for Cancer Research, Connective Tissue Oncology Society and American Society of Clinical Oncology. He joined Moffitt in 2008.